

CURRICULUM VITAE

ARNOLD S. MONTO, M.D.

Thomas Francis Jr. Collegiate Professor of Public Health
Professor of Epidemiology
Professor of Global Health

CONTACT INFORMATION

University of Michigan
School of Public Health
Department of Epidemiology
1415 Washington Heights
Ann Arbor, Michigan 48109-2029

EDUCATION

Cornell University Medical College M.D. 1958
New York, NY

Cornell University B.A. 1954
Ithaca, NY

POSITIONS

Intern and Assistant Resident in Medicine, Vanderbilt University Hospital, 1958-60

USPHS Post-Doctoral Fellow in Infectious Diseases, Stanford Medical Center, 1960-1962

Staff Member, Virus Diseases Section, Middle America Research Unit, National Institute of Allergy and Infectious Diseases, 1962-1965

Research Associate, Assistant Professor, Associate Professor, and Professor, Department of Epidemiology, School of Public Health, The University of Michigan, 1965-present

Thomas Francis Jr. Collegiate Professor of Public Health, 2010-present

Professor, Global Public Health, 2017-present

PROFESSIONAL EXPERIENCE:

Visiting Scientist, Clinical Research Centre, Northwick Park Hospital, Harrow, England, 1976

Scholar-in-Residence, National Academy of Sciences (Board on Science and Technology for International Development) and Institute of Medicine, 1983-1984

Advisor, Division of Communicable Diseases, World Health Organization, Geneva, Switzerland, 1986-1987

Chairman, Department of Population Planning and International Health and **Director**, Center for Population Planning and International Health, University of Michigan, 1993-1996

Director, University of Michigan Bioterrorism Preparedness Initiative, 2002-2004

Director and Founder, University of Michigan - Israel Public Health Partnership, 2014 - present

HONORS

Career Development Award, NIH

Pulmonary Diseases Advisory Committee, NHLBI

National Advisory Allergy and Infectious Diseases Council, 1989-1993

President, American Epidemiological Society, 2004-05

Alexander Fleming Lifetime Achievement Award, Infectious Diseases Society of America, 2009

Thomas Francis Jr. Lectureship, University of Michigan 2010

Charles Merieux Award, National Foundation for Infectious Diseases, 2012

Arnold S. Monto Award for Epidemiology, established at CDC Influenza Division, 2015

PROFESSIONAL ORGANIZATIONS

American Epidemiological Society

American Association for the Advancement of Science

American Public Health Association

Infectious Diseases Society of America (Fellow)

International Epidemiological Association

Society for Epidemiologic Research

LICENSURE

Medical Doctor, Michigan permanent I.D. #126731

Diplomat, American Board of Medical Microbiology

Diplomat, American College of Epidemiology

CURRENT GRANT SUPPORT

Household Influenza Vaccine Effectiveness Study (HIVE)

Role: Co-Principal Investigator

Date: 8/01/2016 -07/31/2021

Funder: CDC/National Center for Immunization and Respiratory Diseases (NCIRD)

This project is to follow a longitudinal cohort of households to look at the impact of repeated exposure to molecularly distinct influenza and vaccine strains over time.

US Influenza Vaccine Effectiveness (VE) Network

Role: Principal Investigator

Date: 8/01/2016 – 7/31/2021

Funder: National Center for Immunization and Respiratory Diseases (NCIRD)

This cooperative agreement is a five-site network intended to determine the effectiveness of influenza vaccine in preventing medically attended illnesses on an annual basis.

Role: Subcontract PI

Date: 8/30/2017- 8/30/2020

Funder: NIAID Centers of Excellence for Influenza Research and Surveillance (NIAID CEIRS)

US Platform to Measure Influenza Vaccine Effectiveness Against Laboratory-confirmed Influenza-associated Hospitalizations

Role: Principal Investigator

Date: 8/01/2015 - 7/31/2020

Funder: U.S. Centers for Disease Control and Prevention (CDC)

This cooperative agreement is intended to determine on an annual basis the effectiveness of influenza vaccine by collecting and comparing data on laboratory confirmed outpatient influenza cases and controls. Household study funded as an optional component.

SELECTED RECENT SERVICE

International and National

Acting Chair for review of Covid Vaccine Approvals. Vaccines and Related Biological Products Advisory Committee, FDA 2020-present

Member, Vaccines and Related Biological Products Advisory Committee, FDA 2016-2020

Member, President's Council of Advisors on Science and Technology 2009 – H1N1 Working Group, 2009

Acute Respiratory Infections Subcommittee, US/Japan – Cooperative Medical Science Panel, 2010

WHO Influenza Pandemic Emergency Committee, 2009-2010

Board Member, European Scientific Working Group on Influenza, 2009-present

Member, Scientific and Technical Advisory Group, World Health Organization, Global Influenza Programme, 2009- present

Advisory Board, Emory University Center for Excellence in Influenza Research and Surveillance, 2008-present

Pandemic Influenza Task Force, Infectious Disease Society of America, 2007- present

Scientific Committee, Merieux Foundation, 2007-present

Co-chair Neuraminidase Inhibitor Susceptibility Network, 2006-2013

Co-chair, Infectious Disease Society of America Meetings Seasonal and Pandemic Influenza, 2006-2010

World Health Organization Pandemic Influenza Task Force, 2006-2007

Institute of Medicine Committee on Modeling Community Containment for Pandemic Influenza, 2006

Briefing on Pandemic Influenza, Health Committees of House of Commons and Senate, Ottawa, 2006

Briefing on Pandemic Influenza, US State Department, Washington, DC, 2006

Moderator, NIH Meeting on Antivirals for Pandemics, 2006

Pandemic Advisory Group, European Commission, Brussels, 2005

Consultant, DARPA, Department of Defense, Predicting Health and Disease Workshop, 2005

Advisor, Defense Threat Reduction Agency, Department of Defense, 2005-present

PUBLICATIONS

1. Monto AS. The liver in ulcerative disease of the intestinal tract: Functional and anatomic changes. *Ann of Int Med.* 1959; 50:1385-94. PMID: 13661766
2. Vosti KL, Monto AS and Rantz LA. The importance of sample size in studies based upon the serologic classification of *Escherichia coli*. *Proc Soc Exp Biol Med.* 1962; 111:201-4. PMID: 13997965
3. Monto AS and Rantz LA. The development and character of bacteriuria in pregnancy. *Ann Int Med.* 1963; 59:186-93. PMID: 14049347
4. Vosti KL, Monto AS, Older JJ and Rantz LA. The serologic specificity of crude and purified antigen extracts of *Escherichia coli* in hemagglutination reactions with rabbit and human antisera. *J Immun.* 1964; 93:199-204. PMID: 14202246
5. Vosti KL, Goldberg LM, Monto AS and Rantz LA. Host-parasite interaction in patients with infections due to *Escherichia coli*. I. The serogrouping of *E. coli* from intestinal and extraintestinal sources. *J Clin Invest.* 1964; 43:2377-85. PMID: 14234834
6. Monto AS and Rantz LA. Classification of so-called paracolonic bacilli isolated from urinary tract infection. *J Lab Clin Med.* 1965; 65:64-70.
7. Vosti KL, Monto AS, Rantz LA. Host-parasite interaction in patients with infections due to *Escherichia coli* II Serologic response of the host. *J Lab Clin Med.* 1965; 66:613-26. PMID: 4954172
8. Monto AS, Olazabal F Jr. Asian influenza in the Panama Canal zone: isolation of a virus variant and protective

- effect of a vaccine containing A2/Japan/305/57. *Am J Epidemiol.* 1966; 83:101-12. PMID: 5910213
9. Monto AS, Johnson KM. Serologic relationships of the B632 and ECHO-28 rhinovirus strains. *Proc Soc Exp Biol Med.* 1966; 121:615-9. PMID: 4286797
 10. Monto AS, Johnson KM. A community study of respiratory infections in the tropics I Description of the community and observations on the activity of certain respiratory agents. *Am J Epidemiol.* 1967; 86:78-92. PMID: 4951566
 11. Monto AS, Johnson KM. A community study of respiratory infections in the tropics II: The spread of six rhinovirus isolates within the community. *Am J Epidemiol.* 1968; 88:55-68. PMID: 4298480
 12. Monto AS. A community study of respiratory infections in the tropics 3 Introduction and transmission of infections within families. *Am J Epidemiol.* 1968; 88:69-79. PMID: 4298481
 13. Monto AS, Johnson KM. Respiratory infections in the American tropics. *Am J Trop Med Hyg.* 1968; 17:867-74. PMID: 4302276
 14. Monto AS. Prevalence of antistreptolysin O in young Panamanians. *Public Health Rep.* 1969; 84:77-80. PMID: 4975340
 15. Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. *Bull World Health Organ.* 1969; 41:537-42. PMID: 5309469.
 16. Francis T, Monto AS. Letters to the editor. *Am J Public Health Nations Health.* 1969; 59:589. PMID: 18018250
 17. Monto AS, Cavallaro JJ, Brown GC. Attenuated rubella vaccination in families: observations on the lack of fluorescent antibody response and on the use of blood collected on filter paper discs in the hemagglutination-inhibition test. *J Lab Clin Med.* 1969; 74:98-102. PMID: 4892624
 18. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. *J Infect Dis.* 1970; 122:16-25. PMID: 5433709
 19. Monto AS, Cavallaro JJ, Keller JB. Seasonal patterns of acute infection in Tecumseh, Mich. *Arch Environ Health.* 1970; 21:408-17. PMID: 4323374
 20. Monto AS, Cavallaro JJ, Whale EH. Frequency of arthralgia in women receiving one of three rubella vaccines. *Arch Intern Med.* 1970; 126:635-9. PMID: 4918712
 21. Cavallaro JJ, Monto AS. Community-wide outbreak of infection with a 229E-like coronavirus in Tecumseh, Michigan. *J Infect Dis.* 1970; 122:272-9. PMID: 5504709
 22. Monto AS, Napier JA, Metzner HL. The Tecumseh study of respiratory illness I Plan of study and observations on syndromes of acute respiratory disease. *Am J Epidemiol.* 1971; 94:269-79. PMID: 5093655
 23. Monto AS, Cavallaro JJ. The Tecumseh study of respiratory illness II Patterns of occurrence of infection with respiratory pathogens, 1965-1969. *Am J Epidemiol.* 1971; 94:280-9. PMID: 4328569
 24. Monto AS, Lim SK. The Tecumseh study of respiratory illness 3 Incidence and periodicity of respiratory syncytial virus and *Mycoplasma pneumoniae* infections. *Am J Epidemiol.* 1971; 94:290-301. PMID: 4328570
 25. Davenport FM, Monto AS. Practical considerations in the diagnosis of myxovirus infections. *Am J Clin Pathol.* 1972; 57:777-82. PMID: 4337371
 26. Cavallaro JJ, Monto AS. HL cells, a sensitive line for the isolation and propagation of respiratory syncytial virus. *Proc Soc Exp Biol Med.* 1972; 140:507-10. PMID: 4338798
 27. Monto AS, Cavallaro JJ. The Tecumseh study of respiratory illness IV Prevalence of rhinovirus serotypes, 1966-1969. *Am J Epidemiol.* 1972; 96:352-60. PMID: 4344343
 28. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. *Lancet.* 1973; 1:623-5. PMID: 4121842
 29. Monto AS, Brandt BL, Artenstein MS. Response of children to *Neisseria meningitidis* polysaccharide vaccines. *J*

- Infect Dis. 1973; 127:394-400. PMID: 4632878
30. Monto AS. The Tecumseh study of respiratory illness V Patterns of infection with the parainfluenza viruses. *Am J Epidemiol.* 1973; 97:338-48. PMID: 4349692
 31. Monto AS, Ullman BM. Acute respiratory illness in an American community The Tecumseh study. *JAMA.* 1974; 227:164-9. PMID: 4357298
 32. Monto AS, Bryan ER. Microneutralization test for detection of rhinovirus antibodies. *Proc Soc Exp Biol Med.* 1974; 145:690-4. PMID: 4360649
 33. Monto AS, Lim SK. The Tecumseh study of respiratory illness VI Frequency of and relationship between outbreaks of coronavirus infection. *J Infect Dis.* 1974; 129(3):271-6. PMID: 4816305.
 34. Monto AS. Medical reviews Coronaviruses. *Yale J Biol Med.* 1974; 47:234-51. PMID: 4617423
 35. Monto AS, Bryan ER, Rhodes LM. The Tecumseh study of respiratory illness VII Further observations on the occurrence of respiratory syncytial virus and Mycoplasma pneumoniae infections. *Am J Epidemiol.* 1974; 100:458-68. PMID: 4374887
 36. Monto AS, Higgins MW, Ross HW. The Tecumseh study of respiratory illness VIII Acute infection in chronic respiratory disease and comparison groups. *Am Rev Respir Dis.* 1975; 111:27-36. PMID: 163065
 37. Oberhofer TR, Brown GC, Monto AS. Seroimmunity to poliomyelitis in an American community. *Am J Epidemiol.* 1975; 101:333-9. PMID: 164770
 38. Monto AS, Kioumehri F. The Tecumseh Study of Respiratory Illness IX Occurrence of influenza in the community, 1966--1971. *Am J Epidemiol.* 1975; 102:553-63. PMID: 1202957
 39. Monto AS. *Viral Infections of Humans: Epidemiology and Control.* Evans AS, editor. New York: Plenum Medical Book Co.; 1976. Coronaviruses; p.127-41. 584p.
 40. Monto AS, Rhodes LM. Detection of coronavirus infection of man by immunofluorescence. *Proc Soc Exp Biol Med.* 1977; 155:143-8. PMID: 194251
 41. Monto AS, Maassab HF. Use of influenza vaccine in non-high risk populations. *Dev Biol Stand.* 1977; 39:329-35. PMID: 604116
 42. Monto AS, Ross H. Acute respiratory illness in the community: effect of family composition, smoking, and chronic symptoms. *Br J Prev Soc Med.* 1977; 31:101-8. PMID: 884394
 43. Monto AS, Dickson CB, Landis JR. Utilization and acceptability of influenza A/New Jersey/76 virus vaccine in Oakland County, Michigan. *J Infect Dis.* 1977; 136:S693-8. PMID: 606793
 44. Monto AS, Ross HW. The Tecumseh study of respiratory illness X Relation of acute infections to smoking, lung function and chronic symptoms. *Am J Epidemiol.* 1978; 107:57-64. PMID: 623090
 45. Maassab HF, Spring SB, Kendal AP, Monto AS. *Negative Strand Viruses and the Host Cell.* Mahy BW, Barry RD, editors. Massachusetts: Academic Press; 1978. Biologic characteristics of influenza virus recombinants derived at suboptimal temperature; p.721-32.
 46. Austin MA, Monto AS, Maassab HF. Growth characteristics of influenza virus type C in avian hosts Brief report. *Arch Virol.* 1978; 58:349-53. PMID: 736797
 47. Monto AS, Bryan ER. Susceptibility to rhinovirus infection in chronic bronchitis. *Am Rev Respir Dis.* 1978; 118:1101-3. PMID: 217286
 48. Monto AS, Ross HW. Swine influenza vaccine program in the community: acceptability, reactions and responses. *Am J Public Health.* 1979; 69:233-7. PMID: 217281
 49. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. *JAMA.* 1979; 241:1003-7. PMID: 368354
 50. Monto AS, Maassab HF. Effect of cyclic nucleotide on coronavirus replication. *Proc Soc Exp Biol Med.* 1979; 161:183-5. PMID: 221932

51. Fannin KF, Cochran KW, Lamphiear DE, Monto AS. "Acute Illness Differences with Regard to Distance from the Tecumseh, Michigan, Wastewater Treatment Plant" in *Wastewater Aerosols and Diseases, Proceedings of a Symposium September 1979*. Pahren HA, Jakubowski W, editors. Cincinnati, Ohio: U.S. Environmental Protection Agency, EPA #600980028; 1980. p.117-135.
52. Monto AS. *Maxcy-Rosenau Public Health and Preventive Medicine*. 11th ed. Last J, editor. New York: Appleton-Century-Crofts; 1980. Acute respiratory disease; Viral infections of the gastrointestinal tract; p.121-31; 131-5.
53. Monto AS, Koopman JS. The Tecumseh Study XI Occurrence of acute enteric illness in the community. *Am J Epidemiol*. 1980; 112:323-33. PMID: 7424881
54. Luscombe FA, Monto AS, Baublis JV. Mortality due to Reye's syndrome in Michigan: distribution and longitudinal trends. *J Infect Dis*. 1980; 142:363-71. PMID: 7441007
55. Monto AS, Maassab HF, Bryan ER. Relative efficacy of embryonated eggs and cell culture for isolation of contemporary influenza viruses. *J Clin Microbiol*. 1981; 13:233-5. PMID: 7462417
56. Monto AS, Maassab HF. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. *J Clin Microbiol*. 1981; 13:54-7. PMID: 7462419
57. Maassab HF, Monto AS, DeBorde DC, Cox NJ, Kendal SP. ICN-UCLA Symposia on Molecular and Cellular Biology - Genetic Variation among Influenza Viruses. Nayak DP, editor. New York: Academic Press; 1981. Development of cold recombinants of influenza virus as live virus vaccines; p.617-37.
58. Maassab HF, Smitka CW, Donabedian AM, Monto AS, Cox NJ, Kendal AP. The Replication of Negative Strand Viruses. Bishop DH, Compans RS, editors. New York: Elsevier - North Holland, Inc; 1981. Characteristics of influenza virus "cold" recombinants derived at the non-permissive temperature (38°); p.395-404.
59. Monto AS, Maassab HF. Serologic responses to nonprevalent influenza A viruses during intercytic periods. *Am J Epidemiol*. 1981; 113:236-44. PMID: 7193408
60. Monto AS, Ceglarek JP, Hayner NS. Liver function abnormalities in the course of a type A (H1N1) influenza outbreak: relation to Reye's syndrome. *Am J Epidemiol*. 1981; 114:750-9. PMID: 7304602
61. Troisi CL, Monto AS. Comparison of enzyme-linked immunosorbent assay and hemagglutination inhibition in a seroepidemiological study of influenza type C infection. *J Clin Microbiol*. 1981; 14:516-21. PMID: 7309849
62. Miller F, Hussein M, Mancy KH, Hilbert MS, Monto AS, Barakat RM. An epidemiological study of *Schistosoma haematobium* and *S mansoni* infection in thirty-five rural Egyptian villages. *Trop Geogr Med*. 1981; 33:355-65. PMID: 7342382
63. Monto AS, Miller FD, Maassab HF. Evaluation of an attenuated, cold-recombinant influenza B virus vaccine. *J Infect Dis*. 1982; 145:57-64. PMID: 7054318
64. Monto AS. *Viral Infections of Humans: epidemiology and control*. 2nd ed. Evans AS, editor. New York: Plenum Medical Book Publishing Company; 1982. Coronaviruses; p.151-65.
65. Monto AS. Book Review: *Pure Politics and Impure Science: The Swine Flu Affair*. *JAMA*. 1982; 247:3268-69.
66. Koopman JS, Eckert EA, Greenberg HB, Strohm BC, Isaacson RE, Monto AS. Norwalk virus enteric illness acquired by swimming exposure. *Am J Epidemiol*. 1982; 115:173-7. PMID: 6277185
67. King CL, Miller FD, Hussein M, Barkat R, Monto AS. Prevalence and intensity of *Schistosoma haematobium* infection in six villages of upper Egypt. *Am J Trop Med Hyg*. 1982; 31:320-7. PMID: 7072897
68. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. *Am J Epidemiol*. 1982; 115:736-51. PMID: 7081204
69. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. *J Infect Dis*. 1982; 146:780-90. PMID: 7142749

70. Monto AS. Coordination of epidemiologic studies of respiratory infection. *Ped Res.* 1983; 17:1062-4.
71. Longini IM Jr, Koopman JS, Monto AS. [Procedures for estimating transmission parameters from influenza epidemics: use of serological data]. *Vopr Virusol.* 1983; PMID: 6868556
72. Wright PF, Cherry JD, Foy HM, Glezen WP, Hall CB, McIntosh K, Monto AS, Parrott RH, Portnoy B, Tabor LH. Antigenicity and reactivity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety. *Rev Infect Dis.* 1983; 5:758-64. PMID: 6353530
73. Monto AS, Koopman JS, Longini IM, Isaacson RE. The Tecumseh study XII Enteric agents in the community, 1976-1981. *J Infect Dis.* 1983; 148:284-91. PMID: 6310002
74. Monto AS. Prevention and drug treatment of influenza. *Am Fam Physician.* 1983; 28:165-9. PMID: 6650333
75. Koopman JS, Turkish VJ, Monto AS, Gouvea V, Srivastava S, Isaacson RE. Patterns and etiology of diarrhea in three clinical settings. *Am J Epidemiol.* 1984; 119:114-23. PMID: 6691328
76. Higashi GI, Isaacson RE, Monto AS. *Textbook of Public Health.* Holland W, editor. New York: Oxford University Press; 1984. Determinants of health and disease: Infectious agents; p.77-96.
77. Monto AS. Rimantadine prophylaxis of influenza A. *Microbiology.* 1984; 424-6.
78. Longini IM Jr, Monto AS, Koopman JS. Statistical procedures for estimating the community probability of illness in family studies: rhinovirus and influenza. *Int J Epidemiol.* 1984; 13:99-106. PMID: 6321368
79. Monto AS. Epidemiologic designs for the study of acquired immunodeficiency disease: options and obstacles. *Rev Infect Dis.* 1984; 6:720-5. PMID: 6505498
80. Koopman JS, Turkish VJ, Monto AS, Thompson FE, Isaacson RE. Milk fat and gastrointestinal illness. *Am J Public Health.* 1984; 74:1371-3. PMID: 6095691
81. Longini IM Jr, Seaholm SK, Ackerman E, Koopman JS, Monto AS. Simulation studies of influenza epidemics: assessment of parameter estimation and sensitivity. *Int J Epidemiol.* 1984; 13:496-501. PMID: 6519891
82. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. *Antimicrob Agents Chemother.* 1985; 27:102-6. PMID: 2984980
83. Monto AS. Laboratory diagnosis of viral infections. Lennette EH, editor. New York: Marcel Dekker, Inc; 1985. Coronaviruses; p.213-24.
84. Monto AS. *Acute Respiratory Infections in Childhood.* Douglas RM, Kerby-Eaton E, editors. Australia: University of Adelaide Press; 1985. Aetiology of acute respiratory infections in the United States; p.45-7.
85. Monto AS. *Laboratory Diagnosis of Viral Infections.* Lennette EH, editor. New York: Marcel Dekker, Inc; 1985. Parainfluenza viruses; p.385-99.
86. Monto AS. *Acute Respiratory Infections in Childhood.* Douglas RM, Kerby-Eaton E, editors. Australia: University of Adelaide Press; 1985. Prospects for control of rhinovirus and coronavirus infections; p.62-6.
87. Koopman JS, Turkish VJ, Monto AS. Infant formulas and gastrointestinal illness. *Am J Public Health.* 1985; 75:477-80. PMID: 2984949
88. Monto AS, Koopman JS, Longini IM Jr. Tecumseh study of illness XIII Influenza infection and disease, 1976-1981. *Am J Epidemiol.* 1985; 121:811-22. PMID: 4014174
89. Remington PL, Rowley D, McGee H, Hall WN, Monto AS. Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984. *Pediatrics.* 1986; 77:93-8. PMID: 3940363
90. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. *Antimicrob Agents Chemother.* 1986; 29:339-41. PMID: 3521480
91. Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. *J Infect Dis.* 1986; 154:128-33. PMID: 3011917
92. Monto AS, Koopman JS, Bryan ER. The Tecumseh Study of Illness XIV Occurrence of respiratory viruses, 1976-1981. *Am J Epidemiol.* 1986; 124:359-67. PMID: 3017099

93. Schwartz SA, Monto AS. Prophylaxis of acute viral upper respiratory infections with intranasal interferon. *Infect Med.* 1987
94. Monto AS. Influenza: quantifying morbidity and mortality. *Am J Med.* 1987; 82:20-5. PMID: 3591814
95. Monto AS, Bryan ER, Ohmit S. Rhinovirus infections in Tecumseh, Michigan: frequency of illness and number of serotypes. *J Infect Dis.* 1987; 156:43-9. PMID: 3036962
96. Hamparian VV, Colonno RJ, Cooney MK, Dick EC, Gwaltney JM Jr, Hughes JH, Jordan WS, Kapikian AZ, Mogabgab WJ, Monto AS, Phillips CA (in absentia), Rueckert RR, Schieble JH, Stott EJ, DAI Tyrell (in absentia). A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. *Virology.* 1987; 159:191-2. PMID: 3037780
97. Monto AS, Albrecht JK, Schwartz SA. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. *Antimicrob Agents Chemother.* 1988; 32:47-50. PMID: 2831814
98. Longini IM Jr, Monto AS. Efficacy of virucidal nasal tissues in interrupting familial transmission of respiratory agents A field trial in Tecumseh, Michigan. *Am J Epidemiol.* 1988; 128:639-44. PMID: 2843040
99. Betts RF, Hayden FG, Monto AS. Safety and tolerance of a loading dose of rimantadine. *J Resp Dis.* 1989; S42-5.
100. Monto AS. *Viral Infections of Humans.* 3rd ed. Evans AS, editor. New York: Plenum Publishing Company; 1989. Coronaviruses; p.153-67.
101. Monto AS. *New Vaccines: Introduction, Part 2. Reviews of Infectious Diseases.* 1989; 11:S586-S587.
102. Monto AS, Schwartz SA, Albrecht JK. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. *Antimicrob Agents Chemother.* 1989; 33:387-90. PMID: 2543280
103. Monto AS. Acute respiratory infection in children of developing countries: challenge of the 1990s. *Rev Infect Dis.* 1989; 11:498-505. PMID: 2665005
104. Koopman JS, Monto AS. The Tecumseh Study XV: Rotavirus infection and pathogenicity. *Am J Epidemiol.* 1989; 130:750-9. PMID: 2549788
105. Koopman JS, Monto AS, Longini IM Jr. The Tecumseh Study XVI: Family and community sources of rotavirus infection. *Am J Epidemiol.* 1989; 130:760-8. PMID: 2773919
106. Monto AS. *Conn's Current Therapy.* Rakel RE, editor. Philadelphia: WB Saunders; 1990. Influenza 1184p.
107. Sullivan KM, Monto AS, Foster DA. Antibody response to inactivated influenza vaccines of various antigenic concentrations. *J Infect Dis.* 1990; 161:333-5. PMID: 2299213
108. Monto AS, Ohmit S. Respiratory syncytial virus in a community population: circulation of subgroups A and B since 1965. *J Infect Dis.* 1990; 161:781-3. PMID: 2319169
109. Monto AS, Higashi GI, MARRS CF. *Textbook of Public Health.* New York: Oxford University Press; 1991. Determinants of disease: The infectious process.
110. Monto AS. Book Review: *History, Epidemiology: Expectations of life: Study in the demography, statistics, and history of world mortality,* by H.O. Lancaster. *JAMA.* 1991; 265:283.
111. Abdeljaber MH, Monto AS, Tilden RL, Schork MA, Tarwotjo I. The impact of vitamin A supplementation on morbidity: a randomized community intervention trial. *Am J Public Health.* 1991; 81:1654-6. PMID: 1746667
112. Monto AS. *Maxcy-Rosenau-Last Public Health and Preventive Medicine.* 13th ed. Last JM, Wallace RB, editors. Norwalk, Connecticut: Appleton & Lange; 1992. Acute respiratory infections; p.125-30; 145-7. 1257p.
113. Monto AS, Shaw MW. *Laboratory Diagnosis of Viral Infections.* 2nd ed. Lennette EH, editor. New York: Marcel Dekker, Inc; 1992. Coronaviruses; p.319-32.
114. Monto AS, Shaw MW. *Laboratory Diagnosis of Viral Infections.* 2nd ed. Lennette EH, editor. New York:

- Marcel Dekker, Inc; 1992. Parainfluenza viruses; p.573-89.
115. Rampey AH Jr, Longini IM Jr, Haber M, Monto AS. A discrete-time model for the statistical analysis of infectious disease incidence data. *Biometrics*. 1992; 48:117-28. PMID: 1316178
 116. Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NH, Monto AS. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. *Am J Epidemiol*. 1992; 136:296-307. PMID: 1415151
 117. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. *Clin Infect Dis*. 1992; 15:362-7; discussion 368-9. PMID: 1520770
 118. Abdeljaber MH, Monto AS, Tilden RL, Schork A. Response Letter: Abdeljaber and Colleagues Respond. *American Journal of Public Health*. 1993; 83:289.
 119. Monto AS. Maxcy-Rosenau-Last Public Health and Preventive Medicine. 14th ed. Wallace RB, editor. Stamford, Connecticut: Appleton & Lange; 1993. Acute respiratory infections; p.169-74. 1291p.
 120. Arden N, Bidol S, Ohmit S, Monto AS. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Effect of nursing home size and influenza vaccination rates on the risk of institutional outbreaks during an influenza A (H3N2) epidemic; p.161-5.
 121. Monto AS, Ohmit SE, Foster DA, Furumoto-Dawson A, Arden NA. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Case-control study in Michigan on prevention of hospitalization by vaccination, 1989-1991; p.135-41.
 122. Rudenko LG, Slepushkin AN, Kendal AP, Beljaev AL, Burtseva EI, Ivanova VT, Petrov LI, Ghendon YZ, Alexandrova GI, Cox NJ. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Comparative studies of live and inactivated vaccines in Novgorod: Description of study design and results of reactogenicity and immunogenicity of vaccines; p.91-6.
 123. Rudenko LG, Slepushkin AN, Monto AS, Grigorieva EP, Rekstin AR, Brangina VE, Kendal AP, Cox NJ, Ghendon YZ, Alexandrova GI. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Comparative studies of the efficacy of live attenuated and inactivated vaccines in children in Novgorod; p.85-90.
 124. Monto AS, Sullivan KM. Acute respiratory illness in the community Frequency of illness and the agents involved. *Epidemiol Infect*. 1993; 110:145-60. PMID: 8432318
 125. Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, Ghendon YZ, Alexandrova GI. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. *J Infect Dis*. 1993; 168:881-7. PMID: 8376833
 126. Sullivan KM, Monto AS, Longini IM Jr. Estimates of the US health impact of influenza. *Am J Public Health*. 1993; 83:1712-6. PMID: 8259800
 127. Monto AS. Studies of the community and family: acute respiratory illness and infection. *Epidemiol Rev*. 1994; 16:351-73. PMID: 7713184
 128. Monto AS. The common cold: Cold water on hot news. *JAMA*. 1994; 271:1122-4. PMID: 8151858
 129. Slepushkin AN, Rudenko LG, Kendal AP, Monto AS, Beliaev AL, Burtseva EI, Grigor'eva EP, Obrosova-Serova NP, Ivanova VT, Bragina VE. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity]. *Vopr Virusol*. 1994; 39:129-31. PMID: 8091754
 130. Monto AS. Influenza vaccines for the elderly. *N Engl J Med*. 1994; 331:807-8. PMID: 8065412

131. Monto AS. Using antiviral agents to control outbreaks of influenza A infection. *Geriatrics*. 1994; 49:30-4. PMID: 7982583
132. Arden N, Monto AS, Ohmit SE. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic. *Am J Public Health*. 1995; 85:399-401. PMID: 7892927
133. Monto AS, Ohmit SE, Margulies JR, Talsma A. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. *Am J Epidemiol*. 1995; 141:502-6. PMID: 7900716
134. Monto AS. Epidemiology of respiratory viruses in persons with and without asthma and COPD. *Am J Respir Crit Care Med*. 1995; 151:1653-7; discussion 1657-8. PMID: 7735629
135. Ohmit SE, Furumoto-Dawson A, Monto AS, Fasano N. Influenza vaccine use among an elderly population in a community intervention. *Am J Prev Med*. 1995; 11:271-6. PMID: 7495605
136. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. *Antimicrob Agents Chemother*. 1995; 39:2224-8. PMID: 8619572
137. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. *Int J Epidemiol*. 1995; 24:1240-8. PMID: 8824869
138. Monto AS. Viral respiratory infections in the community: epidemiology, agents, and interventions. *Am J Med*. 1995; 99:24S-27S. PMID: 8585553
139. Monto AS. The clinical efficacy of influenza vaccination. *Pharmacoeconomics*. 1996;9 Suppl 3:16-22; discussion 23-5. PMID: 10160482
140. Monto AS. Viral respiratory tract infections in the immunocompetent. *Current Opinion in Infectious Diseases*. 1996; 9:85-88.
141. Monto AS, Ohmit SE. Options for the Control of Influenza III. Brown LE, editor. Amsterdam: Elsevier Science BV; 1996. Effectiveness evaluation of inactivated influenza vaccines: methods and results; p.93-6.
142. Monto AS. Options for the Control of Influenza III. Brown LE, editor. Amsterdam: Elsevier Science BV; 1996. The evolving epidemiology of influenza infection and disease; p.45-9.
143. Monto AS. *Medicine*. Vol 24:9. Levers AM, Sissons P, editors. Abingdon, UK: The Medicine Group (Journals) Ltd; 1996. Infections: Influenza; p.100.
144. Monto AS, Terpenning MS. The value of influenza and pneumococcal vaccines in the elderly. *Drugs Aging*. 1996; 8:445-51. PMID: 8736628
145. Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. *J Clin Epidemiol*. 1996; 49:963-7. PMID: 8780603
146. Monto AS, Iacuzio DA, La Montagne JR. Pandemic Influenza—Confronting a Reemergent Threat. *The Journal of Infectious Diseases*. 1997; 176 Suppl 1:S1-3
147. Monto AS, Marrs C. *Oxford Textbook of Public Health*. Third ed. Oxford, England: Oxford University Press; 1997. Determinants of health and disease: Infectious agents; p.175-98
148. Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. *J Infect Dis*. 1997; 176 Suppl 1:S32-7. PMID: 9240692
149. Monto AS. *Textbook of Influenza*. Nicholson KG, Webster RG, Hay AJ, editors. London: Blackwell Science Ltd.; 1998. Chapter 38, Guidelines for the clinical use of antivirals; p.506-14. 578p.
150. Monto AS. *Topley & Wilson's Microbiology and Microbial Infections*. Ninth ed. London: Arnold; 1998. Viral epidemiology; p.235.
151. Monto AS, Lehmann D. Acute respiratory infections (ARI) in children: prospects for prevention. *Vaccine*. 1998; 16:1582-8. PMID: 9711807
152. Monto AS. Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. *Epidemiol*

Rev. 1999;21:7-23. PMID: 10520470

153. Monto A. *Managing Influenza in Primary Care*. 1st ed. Nicholson KG, editor. Oxford, England: Wiley-Blackwell; 1999. Foreword; p.xi-xii.
154. Monto AS. Individual and community impact of influenza. *Pharmacoeconomics*. 1999;16 Suppl 1:1-6. PMID: 10623371
155. Monto AS. *Advances in Influenza*. International Medical Forum 104. Zambon MC, editor. Madrid, Spain. Oxford, Great Britain: Blackwell Science Ltd; 1999. The role of antivirals in prophylaxis; p.39-44.
156. Monto AS. *Viral Infections of the Respiratory Tract*. Dolan R, Wright PF, editors. New York: Marcel Dekker, Inc; 1999. Therapy of viral respiratory infections; p.327-53.
157. Monto AS. *Current Treatment Options*. PA: Current Science Inc; 1999. The prevention and treatment of influenza.
158. Monto AS, Marris C. *Oxford Textbook of Public Health*. Third ed. New York and London: Oxford University Press; 1999. Determinants of health and disease: Infectious agents
159. Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. *J Am Geriatr Soc*. 1999; 47:165-71. PMID: 9988287.
160. Monto AS. Interrupting the transmission of respiratory tract infections: theory and practice. *Clin Infect Dis*. 1999; 28:200-4. PMID: 10064226
161. Monto AS. The disappearance of Reye's syndrome--a public health triumph. *N Engl J Med*. 1999; 340:1423-4. PMID: 10228195
162. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. *JAMA*. 1999; 282:31-5. PMID: 10404908
163. Monto AS, Victor JC. Hepatitis A vaccine for secondary hepatitis A infection. *Lancet*. 1999; 354:341-2; author reply 342-3. PMID: 10440344
164. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON, Man CY. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. *J Infect Dis*. 1999; 180:254-61. PMID: 10395837
165. Monto AS, Gravenstein S, Elliot M, Colopy M, Cobb M, Freund B. Clinical predictors of an acute influenza epidemic with laboratory confirmation. 39th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1999; San Francisco, Calif, US.
166. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. *J Antimicrob Chemother*. 1999; 44 Suppl B:23-9. PMID: 10877459
167. Cram P, Blitz SG, Monto A, Fendrick AM. Diagnostic testing for influenza: review of current status and implications of newer treatment options. *Am J Manag Care*. 1999; 5:1555-61; quiz 1562-3. PMID: 11066622
168. Monto AS. Epidemiology and virology of influenza illness. *The American journal of managed care*. 2000; 6:S255
169. Monto AS, Fendrick AM. Developments in influenza prevention and treatment: A managed care perspective. *Dis Manage Health Outcomes*. 2000; 7:235
170. Monto AS. Acute respiratory infections in childhood: Prospects for vaccine prevention. *Annales Nestle*. 2000; 58:66-73
171. McElroy PD, ter Kuile FO, Lal AA, Bloland PB, Hawley WA, Oloo AJ, Monto AS, Meshnick SR, Nahlen BL. Effect of *Plasmodium falciparum* parasitemia density on hemoglobin concentrations among full-term, normal birth weight children in western Kenya, IV The Asembo Bay Cohort Project. *Am J Trop Med Hyg*. 2000; 62:504-12. PMID: 11220768

172. Monto AS. Preventing influenza in healthy adults: the evolving story. *JAMA*. 2000; 284(13):1699-701. PMID: 11015802
173. Monto AS, Moulton AB, Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms. *Clin Ther*. 2000; 22:1294-305. PMID: 11117654
174. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ. Inhaled zanamivir for the prevention of influenza in families Zanamivir Family Study Group. *N Engl J Med*. 2000; 343:1282-9. PMID: 11058672
175. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. *Arch Intern Med*. 2000 Nov 27;160:3243-7. PMID: 11088084
176. Monto AS. Updating the Approach to Influenza. *Hospital Practice*. 2000; 35(12).
177. Cram P, Blitz SG, Monto AS, Fendrick AM. Influenza: Cost of illness and considerations in the economic evaluation of new and emerging therapies. *Pharmaco Economics*. 2001; 19:223-30. PMID: 11303411
178. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. *JAMA*. 2001; 285:748-54. PMID: 11176912
179. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. *Am J Epidemiol*. 2001; 154:155-60. PMID: 11447049
180. Herlocher ML, Elias S, Truscon R, Harrison S, Mindell D, Simon C, Monto AS. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. *J Infect Dis*. 2001; 184:542-6. PMID: 11494159
181. Monto AS, Fendrick AM, Sarnes MW. Respiratory illness caused by picornavirus infection: a review of clinical outcomes. *Clin Ther*. 2001; 23:1615-27. PMID: 11726001
182. Monto AS. Contemporary Diagnosis, Prevention, and Management of Influenza. First ed. Newton, Pennsylvania: Handbooks in Health Care Co.; 2002. 127p.
183. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. *Am J Manag Care*. 2002; 8:221-7. PMID: 11915972
184. Monto AS. Epidemiology of viral respiratory infections. *Am J Med*. 2002; 112 Suppl 6A:4S-12S. PMID: 11955454
185. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. *Antiviral Res*. 2002; 54:99-111. PMID: 12062395
186. Monto AS. American vaccine recommendations: Rational and effectiveness considerations. 2nd. National Symposium of Advances in Vaccines, Barcelona, Spain. 2002.
187. Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. *J Infect Dis*. 2002; 186:1582-8. PMID: 12447733
188. Monto AS. The seasonality of rhinovirus infections and its implications for clinical recognition. *Clin Ther*. 2002; 24:1987-97. PMID: 12581541.
189. Loughlin J, Poulos N, Napalkov P, Wegmüller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. *Pharmacoeconomics*. 2003; 21:273-83. PMID: 12600222
190. Monto AS. SARS. Chicago, IL: World Book Publishing; 2003.
191. Monto AS, Bramley TJ, Sarnes M. Development of a predictive index for picornavirus infections. *Clin Infect*

- Dis. 2003; 36:253-8. PMID: 12539064
192. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. *Arch Intern Med.* 2003; 163:487-94. PMID: 12588210.
 193. Monto AS. The role of antivirals in the control of influenza. *Vaccine.* 2003; 21:1796-800. PMID: 12686097.
 194. Monto AS. Invited commentary: Use of selective viral cultures to adjust nonvirologic endpoints in studies of influenza vaccine efficacy. *Am J Epidemiol.* 2003; 158:312-5. PMID: 12915496.
 195. Monto AS. Book Review: The global threat of new and reemerging infectious diseases: Reconciling U.S. national security and public health policy. *Am J Epidemiol.* 2003; 158:606
 196. Herlocher ML, Truscon R, Fenton R, Klimov A, Elias S, Ohmit SE, Monto AS. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. *J Infect Dis.* 2003; 188:1355-61. PMID: 14593594
 197. Monto AS. Occurrence of respiratory virus: time, place and person. *Pediatr Infect Dis J.* 2004; 23 Suppl 1:S58-64. PMID: 14730271
 198. Monto AS. Options for the Control of Influenza V. Okinawa, Japan: Elsevier, International Congress Series; 2004. Global burden of influenza: What we know and what we need to know; p.3-11.
 199. Sperber SJ, Shah LP, Gilbert RD, Ritchey TW, Monto AS. Echinacea purpurea for prevention of experimental rhinovirus colds. *Clin Infect Dis.* 2004; 38:1367-71. PMID: 15156472
 200. Monto AS, Rothhoff J, Teich E, Herlocher ML, Truscon R, Yen HL, Elias S, Ohmit SE. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. *Clin Infect Dis.* 2004; 39:459-64. PMID: 15356805
 201. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. *J Infect Dis.* 2004; 190:1627-30. PMID: 15478068
 202. Fleming DM, Monto AS. Correspondence: Influenza Vaccination in Children with Asthma: No reason to change current recommendations. *American Journal of Respiratory and Critical Care Medicine.* 2005; 171:931. PMID: 15817807
 203. Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. *Antivir Ther.* 2005; 10:873-7. PMID: 16430192.
 204. Monto AS. Topley and Wilson's Microbiology and Microbial Infections: Virology Vol. 1. Tenth ed. Mahy BW, Ter Meulen V, editors. London: Hodder Arnold; 2005. The epidemiology of viral infections; p.353-77.
 205. Monto AS. The threat of an avian influenza pandemic. *N Engl J Med.* 2005; 352:323-5. PMID: 15668220
 206. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. *Pediatrics.* 2005; 115:1039-47. PMID: 15805382
 207. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. *J Infect Dis.* 2005; 192:665-72. PMID: 16028136
 208. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. *Antimicrob Agents Chemother.* 2005; 49:4075-84. PMID: 16189083
 209. Cinti S, Chenoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir?. *Infect Control Hosp Epidemiol.* 2005; 26:852-4. PMID: 16320980
 210. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. *Emerg Infect Dis.* 2006; 12:55-60. PMID: 16494718

211. World Health Organization Writing Group: Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, Wylks C, Sanders L, van Tam J. Non-pharmaceutical interventions for pandemic influenza, national and community measures. *Emerg Infect Dis.* 2006; 12:88-94. PMID: 16494723
212. World Health Organization Writing Group: Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, Wylks C, Sanders L, van Tam J. Non-pharmaceutical interventions for pandemic influenza, international measures. *Emerg Infect Dis.* 2006; 12:81-7. PMID: 16494722
213. Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. *Am J Epidemiol.* 2006; 163:204-10. PMID: 16339053
214. Monto AS. Antivirals for influenza in healthy adults. *Lancet.* 2006 May; 367:1571-2; author reply 1573. PMID: 16698401
215. Victor JC, Surdina TY, Suleimeova SZ, Favorov MO, Bell BP, Monto AS. The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity. *Epidemiol Infect.* 2006; 134:492-7. PMID: 16194291
216. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. *Antimicrob Agents Chemother.* 2006; 50:2395-402. PMID: 16801417
217. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. *Clin Infect Dis.* 2006; 43:564-8. PMID: 16886147
218. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. *J Virol.* 2006; 80:8787-95. PMID: 16912325
219. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?. *Pediatrics.* 2006; 118:e570-8. PMID: 16950948
220. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. *Pediatrics.* 2006; 118:e579-85. PMID: 16950949
221. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. *J Infect Dis.* 2006; 194 Suppl 2:S133-8. PMID: 17163386
222. Whitley RJ, Bartlett J, Hayden FG, Pavia AT, Tapper M, Monto AS. Seasonal and pandemic influenza: recommendations for preparedness in the United States. *J Infect Dis.* 2006; 194 Suppl 2:S155-61. PMID: 17163389
223. Whitley RJ, Monto AS. Seasonal and pandemic influenza preparedness: a global threat. *J Infect Dis.* 2006; 194 Suppl 2:S65-9. PMID: 17163390
224. Monto AS, Comanor L, Shay DK, Thompson WW. Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness. *J Infect Dis.* 2006; 194 Suppl 2:S92-7. PMID: 17163395
225. Markel H, Stern AM, Navarro JA, Michalsen JR, Monto AS, DiGiovanni C. Nonpharmaceutical influenza mitigation strategies, US communities, 1918-1920 pandemic. *Emerg Infect Dis.* 2006; 12(12):1961-4. PMID: 17326953. PMCID: PMC3291356. DOI:10.3201/eid1212.060506.
226. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. *N Engl J Med.* 2006; 355:2513-22. PMID: 17167134

227. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. *Am J Epidemiol.* 2007; 165:212-21. PMID: 17088311.
228. Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov MO, Margolis HS, Bell BP. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. *N Engl J Med.* 2007; 357:1685-94. PMID: 17947390
229. Monto AS, Whitley RJ. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. *Clin Infect Dis.* 2008; 46:1024-31. PMID: 18444819
230. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. *J Infect Dis.* 2008; 198:312-7. PMID: 18522501
231. Monto AS. Editorial commentary: viral susceptibility and the choice of influenza antivirals. *Clin Infect Dis.* 2008; 47:346-8. PMID: 18582205
232. Monto AS. Epidemiology of influenza. *Vaccine.* 2008; 26 Suppl 4:D45-8. PMID: 19230159.
233. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling pre-pandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. *Lancet Infect Dis.* 2008; 8:650-8. PMID: 18922487
234. Monto AS. Antivirals and influenza: frequency of resistance. *Pediatr Infect Dis J.* 2008; 27 Suppl 10:S110-2. PMID: 18820569
235. Monto AS. The risk of seasonal and pandemic influenza: prospects for control. *Clin Infect Dis.* 2009; 48 Suppl 1:S20-5. PMID: 19067611
236. Ohmit SE, Gross J, Victor JC, Monto AS. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. *Vaccine.* 2009; 27:1050-4. PMID: 19095028
237. Monto AS. Implications of antiviral resistance of influenza viruses. *Clin Infect Dis.* 2009; 48:397-9. PMID: 19586376
238. Layne SP, Monto AS, Taubenberger JK. Pandemic influenza: an inconvenient mutation. *Science.* 2009; 323:1560-1. PMID: 19299601
239. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. *Expert Rev Vaccines.* 2009; 8:383-9. PMID: 19348555
240. Uyeki TM, Prasad R, Vukotich C, Stebbins S, Rinaldo CR, Ferng YH, Morse SS, Aiello AE, Davis B, Monto AS. Low sensitivity of rapid diagnostic test for influenza. *Clin Infect Dis.* 2009; 48:e89-92. PMID: 19323628
241. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaña LF, Nichol KL, Puig-Barbera J, Schmitt J, Stephenson I. Influenza control in the 21st century: Optimizing protection of older adults. *Vaccine.* 2009; 27:5043-53. PMID: 19559118
242. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. *N Engl J Med.* 2009; 361:1260-7. PMID: 19776407
243. Aiello AE, Murray GF, Perez V, Coulborn RM, Davis BM, Uddin M, Shay DK, Waterman SH, Monto AS. Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. *J Infect Dis.* 2010; 201:491-8. PMID: 20088690
244. Vukotich CJ Jr, Coulborn RM, Aragon TJ, Baker MG, Burrus BB, Aiello AE, Cowling BJ, Duncan A, Enanoria W, Fabian MP, Ferng YH, Larson EL, Leung GM, Markel H, Milton DK, Monto AS, Morse SS, Navarro JA, Park SY, Priest P, Stebbins S, Stern AM, Uddin M, Wetterhall SF. Findings, gaps, and future direction for research in nonpharmaceutical interventions for pandemic influenza. *Emerg Infect Dis.* 2010; 16:e2. PMID: 20350370.

245. Aiello AE, Coulborn RM, Aragon TJ, Baker MG, Burrus BB, Cowling BJ, Duncan A, Enanoria W, Fabian MP, Ferng YH, Larson EL, Leung GM, Markel H, Milton DK, Monto AS, Morse SS, Navarro JA, Park SY, Priest P, Stebbins S, Stern AM, Uddin M, Wetterhall SF, Vukotich CJ Jr. Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research. *Am J Infect Control*. 2010; 38:251-8. PMID: 20226569
246. Uddin M, Cherkowski GC, Liu G, Zhang J, Monto AS, Aiello AE. Demographic and socioeconomic determinants of influenza vaccination disparities among university students. *J Epidemiol Community Health*. 2010; 64:808-13. PMID: 19828514
247. Carney PJ, Lipatov AS, Monto AS, Donis RO, Stevens J. Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins. *Clin Vaccine Immunol*. 2010; 17:1407-16. PMID: 20660137
248. Monto AS. Seasonal influenza vaccinations: specialized products for different target groups. *Vaccine*. 2010; 28 Suppl 4:D14-23. PMID: 20713256
249. Monto AS. Seasonal influenza and vaccination coverage. *Vaccine*. 2010; 28 Suppl 4:D33-44. PMID: 20713259
250. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, Talbot HK, Ohmit SE, Coleman LA, Lofthus G, Petrie JG, Meece JK, Hall CB, Williams JV, Gargiullo P, Berman L, Shay KL. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 US communities. *PLoS One*. 2011;6:e23085. PMID: 21857999
251. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. *J Infect Dis*. 2011; 203:1309-15. PMID: 21378375
252. Monto AS, Black S, Plotkin SA, Orenstein WA. Response to the 2009 pandemic: effect on influenza control in wealthy and poor countries. *Vaccine*. 2011; 29:6427-31. PMID: 21763381
253. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. *J Infect Dis*. 2011; 204:1879-85. PMID: 21998477
254. Aiello AE, Perez V, Coulborn RM, Davis BM, Uddin M, Monto AS. Facemasks, hand hygiene, and influenza among young adults: a randomized intervention trial. *PLoS One*. 2012; 7:e29744. PMID: 22295066
255. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto AS, Siqueira M, Tachiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Shang W. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. *Influenza Other Respir Viruses*. 2012; 6:142-52, e1-5. PMID: 21819547
256. Van Kerkhove MD, Riley S, Lipsitch M, Guan Y, Monto AS, Webster RF, Zambon M, Nicoll A, Peiris JS, Ferguson NM. Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". *Science*. 2012; 336:1506; author reply 1506. PMID: 22723396
257. Perez V, Uddin M, Galea S, Monto AS, Aiello AE. Stress, adherence to preventive measures for reducing influenza transmission and influenza-like illness. *J Epidemiol Community Health*. 2012; 66:605-10. PMID: 21224242
258. Graitcer SB, Dube NL, Basurto-Davila R, Smith PF, Ferdinands J, Thompson M, Uzzicanin A, Gargiullo P, Chaves SS, Robinson S, Sears S, Tipton M, Monto AS, Mills D, Shay DK. Effects of immunizing school children with 2009 influenza A (H1N1) monovalent vaccine on absenteeism among students and teachers in Maine. *Vaccine*. 2012; 30:4835-41. PMID: 22609012
259. Monto AS, Ohmit SE. Editorial commentary: seasonal influenza vaccines during the 2009 pandemic: help or harm? *Clin Infect Dis*. 2012; 55:703-5. PMID: 22670047
260. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall D, Monto AS, Griffin MR, Belongia E, Shay DK, US Flu-VE Network.

- Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. *Clin Infect Dis.* 2012; 55:951-9. PMID: 22843783
261. Uzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, Graitcer S, Jackson R, Ferdinands J, Gargiullo P, Mills D, Monto AS, Shay DK. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. *J Infect Dis.* 2012; 206:1059-68. PMID: 22850120
 262. Petrie JG, Ohmit SE, Cowling BJ, Johnson E, Cross RT, Malosh RE, Thompson MG, Monto AS. Influenza transmission in a cohort of households with children: 2010-2011. *PLoS One.* 2013; 8:e75339. PMID: 24086511
 263. Monto AS, Webster RG. *Textbook of Influenza*. 2nd ed. Webster RG, Monto AS, Braciale TJ, Lamb RA, editors. Chichester, UK: Wiley & Sons, Ltd; 2013. Influenza pandemics: History and lessons learned; p.20-33.
 264. Widdowson MA, Monto AS. *Textbook of Influenza*. 2nd ed. Webster RG, Monto AS, Braciale TJ, Lamb RA, editors. Chichester, UK: Wiley & Sons, Ltd; 2013. Epidemiology of influenza; p.250-65.
 265. Monto AS. *Pandemic Influenza*. 2nd ed. Van-Tam J, Sellwood C, editors. Wallingford, UK: CAB International; 2013. History and epidemiological features of pandemic influenza; p.40-8.
 266. Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS). *Clin Infect Dis.* 2013; 56:1197-205. PMID: 23307766
 267. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. *Clin Infect Dis.* 2013; 56:1363-9. PMID: 23413420
 268. Gessner BD, Brooks WA, Neuzil KM, Vernet G, Bright RA, Tam JS, Bresee J, Monto AS. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). *Vaccine.* 2013; 31:3222-8. PMID: 23707161
 269. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus ADME. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. *Vaccine.* 2013; 31:6030-3. PMID: 24095882
 270. Monto AS, Cowling BC, Peris J. *Viral Infections of Humans: Epidemiology and Control*. 5th ed. Kaslow RA, Stanberry LR, Le Duc JW, editors. New York: Springer Science & Business Media; 2014. Coronaviruses; p.199-223.
 271. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, Jackson L, Meece JL, Nowalk MP, Song J, Zervos M, Cheng PY, Rinaldo CR, Clipper L, Shay KL, Piegra P, Monto AS. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. *Clin Infect Dis.* 2014; 58:319-27. PMID: 24235265
 272. Malosh R, Ohmit SE, Petrie JG, Thompson MG, Aiello AE, Monto AS. Factors associated with influenza vaccine receipt in community dwelling adults and their children. *Vaccine.* 2014; 32:1841-7. PMID: 24530926
 273. Havers F, Thaker S, Clippard JR, Jackson M, McLean HQ, Gaglani M, Monto AS, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Glannery B, Thompson MG, Fry AM. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. *Clin Infect Dis.* 2014; 59:774-82. PMID: 25034419
 274. Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons. *J Infect Dis.* 2014; 210:1792-9. PMID: 24907381
 275. de Jong MD, Ison MG, Monto AS, Metev H, Clark C, O'Neil B, Elder J, McCullough A, Collis P, Sheridan WP. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. *Clin Infect Dis.* 2014; 59:e172-85. PMID: 25115871

276. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet*. 2015; 385:1729-37. PMID: 25640810
277. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. *J Infect Dis*. 2015; 211:1519-28. PMID: 25416812
278. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman RK, Nowalk MP, Raviotta JM, Jackson ML, Jackson L, Ohmit SE, Petrie JG, Monto AS, Meece JK, Thaker SN, Clippard JR, Spencer SM, Fry AM, Belongia EA. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. *J Infect Dis*. 2015; 211:1529-40. PMID: 25406334
279. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. *J Infect Dis*. 2015; PMID: 26014800
280. Havers F, Flannery B, Clippard JR, Gaglani M, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Eng HF, Lamerato L, Campbell AP, Fry AM. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. *Clin Infect Dis*. 2015; 60:1677-80. PMID: 25722198
281. Davis BM, Markel H, Navarro A, Wells E, Monto AS, Wells E, Monto AS, Aiello AE. The effect of reactive school closure on community influenza-like illness counts in the state of Michigan during the 2009 H1N1 pandemic. *Clin Infect Dis*. 2015; 60:e90-7. PMID: 25896795
282. Jackson ML, Jackson LA, McClure D, Gaglani M, Murthy K, Malosh R, Monto A, Zimmerman RK, Foppa IM, Flannery B, Thompson MG. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. *Vaccine*. 2015; 33:5181-7. PMID: 26271827
283. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. Antibody to influenza virus neuraminidase: an independent correlate of protection. *J Infect Dis*. 2015; 212:1191-9. PMID: 25858957
284. van Essen GE, Openshaw P, Myles P, Monto A, van der Vries E. Conference Report. How should influenza be treated? Focus on antivirals. *Vaccine* 2015; 33:7033-6. PMID: 26256525
285. Petrie JG, Cheng C, Malosh RE, VanWormer JJ, Flannery B, Zimmerman RK, Gaglani M, Jackson ML, King JP, Nowalk MP, Benoit J, Robertson A, Thaker SN, Monto AS, Ohmit SE. Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. *Clin Infect Dis*. 2016; 62:448-55. PMID:26565004
286. Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B, Martens C, Cheng C, Fry AM, Monto AS. Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. *J Infect Dis*. 2016; 213:1229-36. PMID:26597255
287. Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, Reis EC, Flannery B, Monto AS, Jackson L, Belongia EA, Murthy K, Zimmerman RK, Thaker S, Fry AM. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 months to 8 Years Old during 2011-2012 and 2012-2013: The Importance of Two Priming Doses. *Pediatr Infect Dis J*. 2016; 35:299-308. PMID:26658375
288. Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. *Pediatrics*. 2016; 137:e20153279. PMID:26738884
289. Gaglani M, Pruszyński J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza

- A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. *J Infect Dis*. 2016 213:1546-56. PMID: 26743842
290. Zhao X, Fang VJ, Ohmit SE, Monto AS, Cook AR, Cowling BJ. Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials. *Epidemiology*. 2016; 27:143-51. PMID: 26427723
 291. Petrie JG, Ohmit SE, Truscon R, Johnson E, Braun TM, Levine MZ, Eichelberger MC, Monto AS. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season. *J Infect Dis*. 2016; 214:1142-9. PMID:27095420
 292. Aiello AE, Simanek AM, Eisenberg MC, Walsh AR, Davis B, Volz E, Cheng C, Rainey JJ, Uzicanin A, Gao H, Osgood N, Knowles D, Stanley K, Tarter K, Monto AS. Design and methods of a social network isolation study for reducing respiratory infection transmission: The ex-flu cluster randomized trial. *Epidemics* 2016; 15:38-55. PMID:27266848
 293. Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. *J Infect Dis* 2016; 214:1010-19. PMID: 27190176
 294. Petrie JG, Ohmit SE, Cheng CK, Martin ET, Malosh RE, Luring AS, Lamerato LE, Reyes KC, Flannery B, Ferdinands JM, Monto AS. Influenza Vaccine Effectiveness against Antigenically Drifted Influenza Higher than Expected in Hospitalized Adults: 2014-2015. *Clin Infect Dis*. 2016; 63:1017-25. PMID: 27369320
 295. Zimmerman RK, Balasubramani GK, Nowalk MP, Eng H, Urbanski L, Jackson ML, Jackson LA, McLean HQ, Belongia EA, Monto AS, Malosh RE, Gaglani M, Clipper L, Flannery B, Wisniewski SR. Classification and Regression Tree (CART) analysis to predict influenza in primary care patients *BMC Infect Dis*. 2016; 16:503. PMID: 27659721
 296. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B. 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. *Clin Infect Dis* 2016. PMID: 27702768
 297. Debbink K, McCrone JT, Petrie JG. Vaccination has minimal impact on the intrahost diversity of h3n2 influenza viruses. 2017;13:e1006194. PMID: 28141862
 298. Monto AS. Moving toward improved influenza vaccines. *J Infect Dis* 2017;215:500-2. PMID: 28329073
 299. Petrie JG, Parkhouse K, Ohmit SE, Malosh RE, Monto AS, & Hensley SE. (2016). Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains. *J Infect Dis*, 2016; 214(12):1947-51. PMID: 27923954
 300. Petrie JG, Monto AS. Untangling the effects of prior vaccination on subsequent influenza vaccine effectiveness. *J Infect Dis* 2017; 215(6):841-843. PMID: 28453852
 301. Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, Truscon R, Eichelberger MC, Gubareva LV, Fry AM, Monto AS. The household influenza vaccine effectiveness study: Lack of antibody response and protection following receipt of 2014-2015 influenza vaccine. *Clin Infect Dis* 2017; 65(10):1644-1651. PMID: 29020179
 302. Petrie JG, Eisenberg MC, Ng S, Malosh RE, Lee KH, Ohmit SE, Monto AS. Application of an individual-based transmission hazard model for estimation of influenza vaccine effectiveness in a household cohort. *Am J Epidemiol* 2017; 186 (12): 1380-1388. PMID: 28605429
 303. Fell DB, Bhutta ZA, Hutcheon JA, Karron RA, Knight M, Kramer MS, Monto AS, Swamy GK, Ortiz JR, Savitz DA. Report of the WHO technical consultation on the effect of maternal influenza and influenza

- vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. *Vaccine* 2017;35:2279-87. PMID:28343772
304. Monto AS, Malosh RE, Petrie JG, Martin ET. The doctrine of original antigenic sin: Separating good from evil. *J Infect Dis* 2017. PMID: 28398521
 305. Malosh RE, Martin ET, Callear AP, Petrie JG, Luring AS, Lamerato L, Fry AM, Ferdinands J, Flannery B, Monto AS. Respiratory syncytial virus hospitalization in middle-aged and older adults. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2017;96:37-43. PMID: 28942341
 306. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Fry AM, Flannery B. Influenza vaccine effectiveness in the United States during the 2015-2016 season. *N Engl J Med* 2017;377:534-43. PMID: 28792867
 307. Chung JR, Flannery B, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Petrie JG, Martin ET, Monto AS, McLean HQ, Belongia EA, Gaglani M, Fry AM. Prior-season vaccination and risk of influenza during the 2014-2015 season in the United States. *J Infect Dis* 2017;216:284-5. PMID: 28633308
 308. Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson L, Jackson ML, Monto AS, Martin ET, Belongia EA, McLean HQ, Fry AM, Havers FP. Influenza antiviral prescribing for outpatients with an acute respiratory illness and at high risk for influenza-associated complications during five influenza seasons-united states, 2011-2016. *Clin Infect Dis* 2019;66(7): 1035-1041. PMID: 29069334.
 309. Petrie JG, Malosh RE, Cheng CK, Ohmit SE, Martin ET, Johnson E, Truscon R, Eichelberger MC, Gubareva LV, Fry AM, Monto AS. The household influenza vaccine effectiveness study: Lack of antibody response and protection following receipt of 2014-2015 influenza vaccine. *Clin Infect Dis* 2017;65:1644-51. PMID: 29020179
 310. Ainslie KEC, Haber MJ, Malosh RE, Petrie JG, Monto AS. Maximum likelihood estimation of influenza vaccine effectiveness against transmission from the household and from the community. *Stat Med* 2018; 37(6):970-982. PMID: 29193179
 311. Lina B, Boucher C, Osterhaus A, Monto AS, Schutten M, Whitley RJ, Nguyen-Van-Tam JS. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza a infections in the influenza resistance information study. *Influenza Other Respir Viruses* 2018;12(2):267-278. PMID: 29265727
 312. Malosh RE, Martin ET, Ortiz JR, Monto AS. The risk of lower respiratory tract infection following influenza virus infection: A systematic and narrative review. *Vaccine* 2018;36:141-7. PMID: 29157959
 313. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and safety of oseltamivir in children: Systematic review and individual patient data meta-analysis of randomized controlled trials. *Clin Infect Dis* 2018; 66:1492-1500. PMID: 29186364
 314. Flannery B, Smith C, Garten RJ, Levine MZ, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman R, Nowalk MP, Griffin MR, Keipp Talbot H, Treanor JJ, Wentworth DE, Fry AM.. Influence of birth cohort on effectiveness of 2015-2016 influenza vaccine against medically attended illness due to 2009 pandemic influenza a(h1n1) virus in the united states. *J Infect Dis* 2018;218:189-196. PMID: 29361005
 315. Davis BM, Foxman B, Monto AS, Baric RS, Martin ET, Uzicanin A, Rainey JJ, Aiello AE. Human coronaviruses and other respiratory infections in young adults on a university campus: Prevalence, symptoms, and shedding. *Influenza Other Respir Viruses* 2018;12(5):582-590. PMID: 29660826
 316. Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. *MMWR Morb Mortal Wkly Rep* 2018;67:180-5. PMID: 29447141

317. Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM. Interim estimates of 2017-18 seasonal influenza vaccine effectiveness - United States, February 2018. *Am J Transplant* 2018;18:1020–5. PMID: 29603606
318. Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE. Identification of human vaccines that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. *Vaccine* 2018;36:4095–101. PMID: 29861178
319. Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS. NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? *MBio* 2018;9(2). PMID: 29615508
320. McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Luring AS. Stochastic processes constrain the within and between host evolution of influenza virus. *Elife* 2018;7. PMID: 29683424.
321. Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Flannery B, Fry AM. Outpatient antibiotic prescribing for acute respiratory infections during influenza seasons. *JAMA Newt Open* 2018;1:e180243.
322. Monto AS. Reflections on The Global Influenza Surveillance and Response System (GISRS) at 65 Years: An Expanding Framework for Influenza Detection, Prevention and Control. *Influenza Other Respir Viruses* 2018;12:10–2. PMID: 29460424
323. Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Flannery B. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. *Vaccine* 2018;36:1272–8. PMID: 29402578
324. Segaloff HE, Petrie JG, Malosh RE, Cheng CK, McSpadden EJ, Ferdinands JM, Lamerato L, Luring AS, Monto AS, Martin ET. Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016. *Epidemiol Infect* 2018;146:1350–8. PMID: 29880077
325. Flannery B, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Rolfes MA, Spenser S, Fry AM, US Flu VE Investigators. Influenza Vaccine Effectiveness in the United States during the 2016-2017 Season. *Clin Infect Dis* 2018;68(11):1789-1806. PMID: 30204854
326. Davis AKF, McCormick K, Gumina ME, Petrie JG, Martin ET, Xue KS, Bloom JD, Monto AS, Bushman FD, Hensley SE. Sera from individuals with narrowly focused influenza virus antibodies rapidly select viral escape mutations in ovo. *J Virol* 2018;92(19). PMID: 30045982.
327. Havers FP, Ching JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG, Fry AM, Flannery B. Influenza vaccine effectiveness and statin use among adults in the United States, 2011-2017. *Clin Infect Dis* 2018;68(1):1616-1622. PMID: 30371753
328. Hirsch A, Katz MA, Laufer Peretz A, Greenberg D, Wendlandt R, Shemer Avni Y, Newes-Adeyi G, Gofer I, Leventer-Roberts M, Davidovitch N, Rosenthal A, Gue-Arie R, Hertz T, Glatman-Freedman A, Monto AS, Azziz-Baumgartner E, Fertinands JM, Martin ET, Malosh RE, Neyra Quijandría JM, Levine M, Campbell W, Balicer R, Thompson MG, SHIRI Workgroup. Study of healthcare personnel with influenza and other respiratory viruses in Israel (SHIRI): study protocol. *BMC Infect Dis* 2018; 18:550. PMID: 30400834
329. Appiah GD, Chung JR, Flannery B, Havers FP, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Gaglani M, Murthy K, Jackson LA, Jackson ML, Mclean HQ, Belgonia EA, Fry AM. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16. *Influenza Other Respir Viruses* 2018;13(2). PMID: 30408341
330. Shang M, Chung JR, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Fry AM, Flannery B. Influenza vaccine effectiveness among patients

- with high-risk medical conditions in the United States, 2012-2016. *Vaccine* 2018;36:8047-8053. PMID: 30420119
331. Ferdinands JM, Gaglani M, Martin ET, Middleton D, Monto AS, Murthy K, Silveira FP, Talbot HK, Zimmerman R, Alyank E, Strickland C, Spencer S, Fry AM, HAIVEN Study Investigators. Prevention of influenza hospitalization among adults in the US, 2015-16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). *J Infect Dis* 2019;220(8):1265-1275. PMID: 30561689
 332. Christensen SR, Toulmin SA, Griesman T, Lamerato LE, Petrie JG, Martin ET, Monto AS, Hensley SE. Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans. *J Virol* 2019;(8)e02134-18. PMID: 30700610
 333. Rolfes MA, Flannery B, Chung J, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman R, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres S, Yousey-Hindes K, Singleton J, Patel M, Reed C, Fry AM; U.S. Flu VE Network, the Influenza Hospitalization Surveillance Network (FluSurv-NET), and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. *Clin Infect Dis* 2019; 69(11):1845-1853. PMID: 30715278.
 334. Eichelberger MC, Monto AS. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. *J Infect Dis* 2019; 219 (Suppl_1): S75-S80 PMID: 30715357.
 335. Levine MZ, Martin ET, Petrie JG, Lauring AS, Holiday C, Jefferson S, Fitzsimmons WJ, Johnson E, Ferdinands JM, Monto AS. Antibodies against egg- and cell-grown influenza A(H3N2) viruses in adults hospitalized during the 2017-2018 season. *J Infect Dis* 2019; 219 (12):1904-1912. PMID: 30721982.
 336. Zelner J, Petrie JG, Trangucci R, Martin ET, Monto AS. Effects of sequential influenza A(H1N1)pdm09 vaccination on antibody waning. *J Infect Dis* 2019; 2019;220(1):12-19.PMID: 30722022.
 337. Malosh RE, Noppert GA, Zelner J, Martin ET, Monto AS. Social patterning of acute respiratory illnesses in the Household Influenza Vaccine Evaluation (HIVE) Study 2014-2015. *Epidemiol Infect* 2019;147:e185. PMID: 31063118
 338. Rolfes MA, Flannery B, Chung JR, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman RK, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres SM, Yousey-Hindes K, Singleton JA, Patel M, Reed C, Fry AM; US Influenza Vaccine Effectiveness (Flu VE) Network, the Influenza Hospitalization Surveillance Network, and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention. Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season. *Clin Infect Dis* 2019. PMID: 30715278
 339. Segaloff HE, Leventer-Roberts M, Riesel D, Malosh RE, Feldman BS, Shemer-Avni Y, Key C, Monto AS, Martin ET, Katz MA. Influenza Vaccine Effectiveness Against Hospitalization in Fully and Partially Vaccinated Children in Israel; 2015-16, 2016-17, and 2017-18. *Clin Infect Dis* 2019. PMID: 30753347
 340. Petrie JG, Martin ET, Truscon R, Johnson E, Cheng CK, McSpadden EJ, Malosh RE, Lauring AS, Lamerato LE, Eichelberger MC, Ferdinands JM, Monto AS. Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population. *Vaccine* 2019;37:1284-92. PMID: 30738647
 341. Monto AS, Malosh RE, Evans R, Lauring AS, Gordon A, Thompson MG, Fry AM, Flannery B, Ohmit SE, Petrie JG, Martin ET; HIVE Study Research Staff. Data resource profile: Household Influenza Vaccine Evaluation (HIVE) Study. *Int J Epidemiol* 2019; 48(4):1040-1040g. PMID: 31038700
 342. Monto AS, Petrie JG. Improving influenza vaccine effectiveness: ways to begin solving the problem. *Clin Infect Dis* 2019. PMID: 31102404

343. Gilbert PB, Fong Y, Juraska M, Carpp LN, Monto AS, Martin ET, Petrie JG. HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. *BMC Infect Dis* 2019;19:453. PMID: 31117986
344. Petrie JG, Martin ET, Zhu Y, Wyatt DG, Kanicliides A, Ferdinands JM, Monto AS, Trabue C, Talbot HK. Comparison of a frailty short interview to a validated frailty index in adults hospitalized for acute respiratory illness. *Vaccine* 2019;37:3849–55. PMID: 31106811
345. Monto AS, Fukuda K. Lessons from Influenza Pandemics of the last 100 Years. *Clin Infect Dis* 2019. PMID: 31420670
346. Monto AS. Effectiveness of the Neuraminidase Inhibitors: The Supporting Evidence Increases. *J Infect Dis*. 2020;221(3):340-342. PMID: 31106811
347. Monto AS. Effectiveness of the Live Attenuated Influenza Vaccine: Was the Addition of the Second Type B Lineage a Step Too Far?. *Clin Infect Dis*. 2020;70(12):2514-2516. PMID: 31408517
348. Whitley RJ, Monto AS. Resistance of Influenza Virus to Antiviral Medications. *Clin Infect Dis*. 2020;71(4):1092-1094. PMID: 31538179
349. Segaloff HE, Cheng B, Miller AV, Petrie JG, Malosh, RE, Cheng, C, Luring, AS, Lamerato, LE, Ferdinands, JM, Monto, AS, Martin, ET. Influenza Vaccine Effectiveness in the Inpatient Setting: Evaluation of Potential Bias in the Test-Negative Design by Use of Alternate Control Groups. *Am J Epidemiol*. 2020;189(3):250-260. PMID: 31673696.
350. Dawood SF, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B. Influenza Estimates of 2019-2020 Season Influenza Vaccine Effectiveness- United States, February 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(7):177-182.
351. Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Foust A, Sessions W, Berman L, Garten RJ, Barnes JR, Wentworth DE, Fry AM, Patel MM, Flannery B. Influenza Estimates of 2018-2019 Season Influenza Vaccine Effectiveness- United States, February 2019. *MMWR Morb Mortal Wkly Rep*. 2020;68(7):135-139.
352. Tenforde MW, Chung J, Smith ER, Talbot HK, Trabue CH, Zimmerman RK, Silveira FP, Gaglani M, Murthy K, Monto AS, Martin ET, McLean HQ, Belongia EA, Jackson LA, Jackson ML, Ferdinands JM, Flannery B, Patel MM. Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015–2018. *Clin Infect Dis*. 2020. (advance/e publication). PMID: 32270198
353. Flannery B, Kondor RJG, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Kim SS, Blanton L, Kniss K, Budd AP, Brammer L, Stark TJ, Barnes JR, Wentworth DE, Fry AM, Patel M, Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018–2019 Season, *J Infect Dis*, 2020; 221(1):8–15, DOI:10.1093/infdis/jiz543.
354. Balasubramani GK, Choi WS, Nowalk MP, Zimmerman RK, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Jackson ML, Jackson LA, Chung JR, Spencer S, Fry AM, Patel M, Flannery B; US Flu VE Network Investigators. . Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015–16 to 2018–19. *Vaccine*. 2020;38(42):6562-6569. PMID: 32800465
355. Kim SS, Foppa I, Chung JR, Belongia E, McLean H, Monto A, Petrie, JG, Zimmerman R, Nowalk MP, Gaglani M, Murthy K, Jackson ML, Flannery B, Patel M. 2760. Accounting for Vaccination History in Estimates of Current Season Vaccine Effectiveness in the US Flu VE Network, 2012–2013 Through 2017–2018. *Open Forum Infect. Dis*. 2020;6(2):S973. PMID: PMC6810001
356. OLeary ST, Ellingson M, Spina C, Brewer SE, Quick L, Chamberlain A, et al. 2735. Improving Uptake of

- Maternal Immunizations in the Obstetric Care Setting Through an Adaptation of the CDC's Immunization Quality Improvement Program (AFIX). *Open Forum Infect. Dis.* 2019;6(2):S962-S963. PMID: PMC6809483
357. Chung JR, Flannery B, Gaglani M, Reis E, Hickey R, McLean H, Jackson ML, Belongia E, Smith M, Martin ET, Monto AS, Thompson MG, Kim SS, Patel M. 900. Effect of Influenza Vaccine Priming on Current Season Vaccine Effectiveness among Children and Adolescents, US Flu VE Network 2014–2015 Through 2017–2018. *Open Forum Infect. Dis.* 2019; 6(Suppl 2):S27. PMID: PMC6808695.
358. DeJonge P, Malosh R, Truscon R, Johnson E, Foote S, Cheng B, Tiseo KE, Getz AS, Segaloff H, Monto AS, Martin ET. 1642. Comparing Viral Respiratory Infections Between Children Who Do and Do Not Attend Child Care. *Open Forum Infect. Dis.* 2019;6(Suppl 2):S599. PMID: PMC6810424
359. Malosh RE, Petrie JG, Callear AP, Monto AS, Martin ET. Home collection of nasal swabs for detection of influenza in the Household Influenza Vaccine Evaluation Study. medRxiv. 2020.
360. Roosenhoff R, Reed V, Kenwright A, Schutten M, Boucher CA, Monto A, Clinch B, Kumar D, Whitley R, Nguyen-Van-Tam JS, Osterhaus ADME, Fouchier RAM, Fraaij PLA. Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). *Clin Infect Dis.* 2020;71(5):1186-1194. PMID: 31560055
361. Smith ER, Fry AM, Hicks LA, Fleming-Dutra KE, Flannery B, Ferdinands J. Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. *Clin Infect Dis.* 2020. (advance/e publication). PMID: 32322875
362. DeJonge P, Malosh R, Tuscon R, Johnson E, Foote S, Cheng B. 1642. Comparing Viral Respiratory Infections Between Children Who Do and Do Not Attend Child Care. *Open Forum Infect. Dis.* 2019;6(Suppl 2): S599. PMID: PMC6810424
363. Doyle JD, Beacham L, Martin ET, Talbot HK, Monto A, Gaglani M, Middleton DB, Silveira FP, Zimmerman RK, Alyanak E, Smith ER, Flannery BL, Rolfes M, Ferdinands JM. Relative and absolute effectiveness of high-dose and standard-dose influenza vaccine against influenza-related hospitalization among older adults - United States, 2015-2017. *Clin Infect Dis.* 2020; Epub ahead of print. PMID: 32067049.
364. Chung JR, Rolfes MA, Flannery B, Prasad P, Holloran AO. Effects of Influenza Vaccination in the United States During the 2018-2019 Influenza Season. *Clin Infect Dis.* 2021;69(11):1845-1853. PMID: 30715278.
365. Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020 [published correction appears in *MMWR Morb Mortal Wkly Rep.* 2020 27;69(12):358]. 0;69(7):177-182.. doi:10.15585/mmwr.mm6907a1
366. Tenforde MW, Talbot HK, Trabue CH, Gaglani M, McNeal TM, Monto AS, Martin ET, Zimmerman RK, Silveira F, Middleton DB, Olson SM, Garten Kondor RJ, Barnes JR, Ferdinands JM, Patel MM; HAIIVEN Investigators. Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019–2020, *J Infect Dis.* 2020 Dec 30;jiaa800. doi: 10.1093/infdis/jiaa800. Epub ahead of print. PMID: 33378531.
367. Kim SS, Flannery B, Foppa IM, Chung JR, Nowalk MP, Zimmerman RK, Gaglani M, Monto AS, Martin ET, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Patel M. Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012–2013 Through 2017–2018, *Clin Infect Dis.* 2020;ciao706, PMID: 32505128.
368. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, Choi CY, Leung K, Chan KH, Chan KC, Li KC, Wu JT, Wilson IA, Monto AS, Poon LL, Peiris M. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), *Euro Surveill.* 2020;25(16) PMID: 32347204 PMID: PMC7189648.
369. Monto AS, DeJonge PM, Callear AP, Bazzi LA, Capriola SB, Malosh RE, Martin, ET, Petrie JG. Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of Households in Michigan, *J Infect Dis.* 2020 16:222(1):9-16. PMID: 32246136.

370. Gouma S, Kim K, Weirick ME, Gumina ME, Branche A, Topham DJ, Martin ET, Monto AS, Cobey S, Hensley SE. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. *Nat Commun*. 2020 11(1):4566. PMID: 32917903; PMCID: PMC7486384.
371. Chotpitayasunondh T, Fischer TK, Heraud JM, Hurt AC, Monto AS, Osterhaus A, Shu Y, Tam JS. Influenza and COVID-19: What does co-existence mean?. *Influenza Other Respi Viruses*. 2020; 00: 1– 6. Epub ahead of print. PMID: 33128444.
372. Ferdinands JM, Gaglani M, Martin ET, Monto AS, Middleton D, Silveira F, Talbot HK, Zimmerman R, Patel M. Waning Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2015–2016 to 2018–2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network, *Clin Infect Dis*, 2021. Epub ahead of print. PMID: 33462610.
373. Valesano AL, Fitzsimmons WJ, McCrone JT, Petrie JG, Monto AS, Martin ET, Luring AS. 2020. Influenza B viruses exhibit lower within-host diversity than influenza A viruses in human hosts. *J Virol* 2020; 94(5):e01710-19. PMID: 31801858; PMCID: PMC7022338.
374. Malosh RE, Petrie JG, Callear A, Truscon R, Johnson E, Evans R, Bazzi L, Cheng C, Thompson MS, Martin ET, Monto AS. Effectiveness of Influenza Vaccines in the HIVE household cohort over 8 years: Is there evidence of indirect protection? *MedRXIV*., 2021. doi: <https://doi.org/10.1101/2021.02.16.21251827>
375. Chung JR, Kim SS, Jackson ML, Jackson LA, Belongia EA, King JP, Zimmerman RK, Nowalk MP, Martin ET, Monto AS, Gaglani M, Smith ME, Patel M, Flannery B. Clinical Symptoms Among Ambulatory Patients Tested for SARS-CoV-2, *Open Forum Infectious Diseases*, 2021; 8(1), 1-4. PMID: 33537361.
376. Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, Belongia EA, McLean HQ, Jackson ML, Jackson LA, Zimmerman RK, Nowalk MP, Monto AS, Martin ET, Chung JR, Spencer S, Fry AM, Flannery B. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017, *Clin Infect Di*. 2021; 72(7):1147–1157. PMID: 32006430.
377. Ghamande S, Shaver C, Murthy K, Raiyani C, White HD, Lat T, Arroliga AC, Wyatt D, Talbot HK, Martin ET, Monto AS, Zimmerman RK, Middleton DB, Silveira FP, Ferdinands JM, Patel MM, Gaglani M. Vaccine effectiveness against acute respiratory illness hospitalizations for influenza-associated pneumonia during the 2015–2016 to 2017–2018 seasons, US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN), *Clinical Infectious Diseases*. 2021;
378. Griggs EP, Flannery B, Foppa IM, Gaglani M, Murthy K, Jackson MJ, Jackson LA, Belongia EA, McLean HQ, Martin ET, Monto AS, Zimmerman RK, Balasubramani GK, Chung JR, Patel M, on behalf of the US Flu VE Investigators, Role of Age in Spread of Influenza, 2011–2019, U.S. Influenza Vaccine Effectiveness Network, *American Journal of Epidemiology*, 2021;, kwab205, <https://doi.org/10.1093/aje/kwab205>